Welcome to our dedicated page for Quoin Pharmaceuticals news (Ticker: QNRX), a resource for investors and traders seeking the latest updates and insights on Quoin Pharmaceuticals stock.
Quoin Pharmaceuticals Ltd (QNRX) is a clinical-stage biopharmaceutical company pioneering therapies for rare dermatological disorders and orphan diseases. This dedicated news hub provides investors and healthcare professionals with timely updates on regulatory milestones, clinical trial progress, and strategic partnerships central to advancing treatments for conditions like Netherton Syndrome and Epidermolysis Bullosa.
Access authoritative information on Quoin's therapeutic pipeline developments, including FDA designations and international trial expansions. The page consolidates official press releases, research collaborations, and manufacturing updates while maintaining strict compliance with financial disclosure standards.
Key content areas include phase trial results, intellectual property announcements, and partnership agreements with biotechnology innovators. All materials are curated to support informed decision-making without speculative commentary or investment recommendations.
Bookmark this page for streamlined tracking of Quoin's progress in addressing unmet medical needs through targeted drug development programs and evidence-based research initiatives.
Quoin Pharmaceuticals (NASDAQ: QNRX) has released the second episode of its 'Living with Netherton' video series, featuring 79-year-old Norma Coles, one of the earliest patients evaluated for Netherton Syndrome. The episode is part of the company's NETHERTON NOW awareness campaign.
Norma's remarkable story spans nearly eight decades, having been initially examined by Dr. Edward Netherton at the Cleveland Clinic in the late 1940s. Despite experiencing symptoms like fragile skin, recurring rashes, and 'bamboo hair,' she wasn't officially diagnosed until her mid-50s.
The company's lead product candidate, QRX003, is currently undergoing four clinical trials for Netherton Syndrome treatment. Initial data shows promising results, including improvements in skin healing, reduction in inflammation and pruritus, and enhanced quality of life. Quoin aims to develop the first FDA-approved treatment for this rare genetic disorder, as currently no approved treatments exist.
Quoin Pharmaceuticals (NASDAQ: QNRX) has reported additional positive clinical data from its ongoing pediatric Netherton Syndrome (NS) study of QRX003. After 6 weeks of whole-body treatment, the first patient's skin remains almost completely healed, demonstrating treatment durability.
Key outcomes include:
- Elimination of previously required medications (antibiotics, antivirals, antihistamines, glucocorticoids)
- Almost complete elimination of pruritus (itching)
- Zero nightly sleep disturbances without sedating medication
- No adverse events reported after 6 weeks
Based on these positive results, Quoin has received approval to begin whole-body QRX003 treatment on a second pediatric NS patient, with testing expected to commence within weeks.
Quoin Pharmaceuticals (NASDAQ: QNRX) has filed a U.S. patent application for novel topical formulations targeting multiple skin diseases, including Netherton Syndrome (NS). The company's lead product, QRX003, is currently undergoing testing in four clinical trials, with three conducted under FDA's Investigational New Drug (IND) application.
The patent application extends to other conditions including Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma, and Severe Atopic Dermatitis. If granted, this would be Quoin's third patent for Netherton Syndrome, providing protection until 2045. The company has reported positive initial clinical data from two open-label studies and is conducting a pediatric NS patient study at Dublin's Children's Hospital, with plans to expand to Spain, UK, and other countries.
Quoin Pharmaceuticals (NASDAQ: QNRX) reported significant progress in 2024, particularly with its lead product QRX003 for Netherton Syndrome. Clinical trials showed promising results, including dramatic reduction in disease severity and skin healing. The company recently received FDA clearance for a 'whole-body' clinical study.
Key developments include filing patent applications for novel topical rapamycin formulations, launching the 'NETHERTON NOW' awareness campaign, and completing a $6.8 million public offering. Positive clinical data showed treatment effectiveness with QRX003, with improvements reversing after discontinuation, supporting the need for chronic treatment.
Financial results show cash position of $14.1 million as of December 31, 2024, expected to fund operations into Q2 2026. Net loss for Q4 2024 was $2.3 million, compared to $2.0 million in Q4 2023, while full-year 2024 net loss was $9.0 million versus $8.7 million in 2023.
Quoin Pharmaceuticals (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company specializing in rare and orphan diseases, has scheduled the release of its Q4 and full-year 2024 financial results for Thursday, March 13, 2025, before market opening.
The upcoming announcement will feature an operational update covering key quarterly achievements, recent accomplishments, and financial highlights from 2024.
Quoin Pharmaceuticals (NASDAQ: QNRX) has filed U.S. and International patent applications for novel topical rapamycin formulations targeting rare diseases including microcystic lymphatic malformations, venous malformations, and angiofibromas. The formulations utilize the proprietary Invisicare delivery technology, designed to optimize skin penetration of rapamycin into the dermis.
The company plans to submit Investigational New Drug (IND) applications and begin clinical testing in 2025 for at least two target indications. Currently, there are no FDA-approved treatments for microcystic lymphatic malformations or venous malformations.
Quoin is also advancing clinical trials for QRX003, their lead product using the same Invisicare technology, which is being tested as a potential first-approved treatment for Netherton Syndrome. The company is actively enrolling patients in three clinical trials under an open IND application for QRX003.
Quoin Pharmaceuticals (NASDAQ: QNRX) has reported significant clinical data from its ongoing Investigator Pediatric Netherton Syndrome (NS) study for QRX003. The first pediatric patient receiving whole-body application showed dramatic improvement after just two weeks of treatment.
Key findings include:
- Investigator's Global Assessment (IGA) improved from 5 to 1 on a 0-10 scale
- Pruritus (itch) score decreased from 7 to 1-2 on a 0-10 scale
- Patient discontinued previously required medications including antihistamines, glucocorticoids, and antivirals
- No antibiotics needed since treatment initiation
- Zero nightly sleep disturbances reported for the first time
- No adverse events observed with twice-daily whole-body application
The company plans to expand the study to include additional pediatric subjects in other countries.
Quoin Pharmaceuticals (NASDAQ: QNRX) announced the launch of its "Living with Netherton" video series, part of the broader NETHERTON NOW campaign. The first episode will premiere on Rare Disease Day, February 28, 2025, featuring Carmon McTigue's story about her son's difficult journey with Netherton Syndrome.
The series aims to raise awareness about this devastating genetic disorder caused by mutations in the SPINK5 gene, which leads to excessive skin shedding, painful inflammation, recurrent infections, and other complications. Up to 20% of babies born with this condition do not survive.
Carmon's story highlights the challenges families face, including delayed diagnosis, misdiagnosis, and lack of treatment options. Her son was hospitalized 15-20 times in his early years due to severe infections.
Quoin's lead candidate, QRX003, is currently being evaluated in four clinical trials, with recent data showing potential efficacy. The video will premiere globally on YouTube at various times across different time zones, with the NETHERTON NOW website serving as a resource hub for patients and families.
Quoin Pharmaceuticals (NASDAQ: QNRX) has launched the 'NETHERTON NOW' campaign to raise awareness about Netherton Syndrome, a rare genetic disease with no approved treatment. The condition affects newborns, with up to 20% mortality rate, causing excessive skin shedding, painful itching, and severe infections.
The company is currently conducting four clinical studies evaluating QRX003, their potential treatment for Netherton Syndrome. Recent clinical data has shown promising results, including photographic evidence of improvement after 12 weeks of treatment. A significant 'whole body' clinical study at Northwestern University, cleared by the FDA, is set to begin.
The campaign includes an interactive website serving as a resource hub for patients and families, providing educational materials and research updates. The initiative aims to address the challenges of diagnosis delays and lack of awareness while supporting the Netherton community through advocacy and education. Interested participants can sign up for clinical study alerts at nethertonnow.com.
Quoin Pharmaceuticals (NASDAQ: QNRX) has announced additional clinical evidence regarding QRX003's effectiveness in treating Netherton Syndrome. After observing positive results during a 12-week treatment period, the company reported that all clinical benefits were completely reversed within 4 weeks of treatment discontinuation.
The clinical data shows that the first subject, who received twice-daily doses, experienced significant improvements across all measured endpoints during the treatment period. The Modified Ichthyosis Area of Severity Index (M-IASI) improved from 18 to 3, the Worst Itch Numeric Rating Scale (WINRS) decreased from 7 to 2, and the Investigator's Global Assessment (IGA) improved from Moderate to Almost Clear. However, these metrics reverted to baseline levels after treatment stopped.
The results indicate that chronic, whole-body treatment with QRX003 is necessary for maintaining positive clinical outcomes in Netherton Syndrome patients. Quoin currently has four clinical studies underway, with three under FDA IND applications, aiming to develop the first approved treatment for this condition.
